Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

Hayato Akimoto, Akio Negishi, Shinji Oshima, Haruna Wakiyama, Mitsuyoshi Okita, Norimitsu Horii, Naoko Inoue, Shigeru Ohshima, Daisuke Kobayashi

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)


Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P <.001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P <.001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P <.001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P =.014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P =.011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.

Original languageEnglish
JournalAmerican Journal of Alzheimer's Disease and other Dementias
Publication statusPublished - 2020
Externally publishedYes


  • Alzheimer disease
  • FDA adverse event reporting system
  • antidiabetics
  • dementia
  • type 2 diabetes mellitus


Dive into the research topics of 'Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS'. Together they form a unique fingerprint.

Cite this